The groundbreaking therapy of the medication represents a significant breakthrough in the management of diabetes mellitus type 2. Different to existing therapies, tirzepatide affects two pathways – GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) – leading to greater sugar control and